The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents

Eur J Med Chem. 2012 Jun:52:242-50. doi: 10.1016/j.ejmech.2012.03.024. Epub 2012 Mar 23.

Abstract

Starting from commercial available natural product oridonin (1), a practical synthesis of ent-6,7-seco-oridonin derivatives (2, 3, 5, and 9) was accomplished and their biological activities were evaluated. The conversion of spirolactone-type diterpenoid to enmein-type was first completed. The results demonstrated that all synthesized ent-6,7-seco-oridonin derivatives could markedly inhibit the proliferation of cancer cells. Compared with Taxol, the most cytotoxic compound 5 has similar potency in A549 cell and slightly less cytotoxicity in Bel-7402 cell. Compound 5 was also more potent than parent compound oridonin in mice with MGC-803 gastric cancer in vivo. Then a series of novel 14-O-derivatives of 5 were further designed and synthesized, which showed better activity than 5 and similar activity as Taxol in vitro. The structure-activity relationships of oridonin derivatives were also discussed in the present investigations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Chemistry Techniques, Synthetic*
  • Diterpenes / chemistry*
  • Diterpenes, Kaurane / chemical synthesis
  • Diterpenes, Kaurane / chemistry*
  • Diterpenes, Kaurane / pharmacology*
  • Female
  • Humans
  • K562 Cells
  • Mice
  • Spironolactone / chemistry*
  • Structure-Activity Relationship
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Diterpenes
  • Diterpenes, Kaurane
  • oridonin
  • Spironolactone
  • enmein